Maia Drasin , Gregory Rumore , Elizabeth Suh-Burgmann
{"title":"Extreme elevation of CA19-9 in patient with endometriosis-associated cancer: A brief report and review of the literature","authors":"Maia Drasin , Gregory Rumore , Elizabeth Suh-Burgmann","doi":"10.1016/j.cpccr.2023.100254","DOIUrl":null,"url":null,"abstract":"<div><p>CA 19-9 (carbohydrate antigen 19-9) is used as a biomarker for hepatobiliary cancer and is generally not considered helpful in the evaluation of gynecologic cancer. Endometriosis-associated cancers are a subset of gynecologic cancers in which malignancy is found adjacent to endometriosis either within or outside the gynecologic tract. We describe a case of a woman who presented with a CA 19-9 level of 49,469 U/mL who was subsequently found to have two concurrent but separate primary endometriosis-associated cancers involving the ovary and small intestine. Although data regarding the association between CA 19-9 and endometriosis-associated malignancy is lacking, endometriosis is known to be associated with high levels of inflammation which in turn has been associated with higher CA 19-9 levels. The inflammatory response and effect on CA 19-9 levels may be particularly pronounced in cases where endometriosis-associated malignancy involves the peritoneum. The case described suggests that when cancer is suspected in a woman with an extremely high level of CA 19-9 and no apparent hepatobiliary disease, an endometriosis-associated malignancy may be a consideration.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621923000388","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
CA 19-9 (carbohydrate antigen 19-9) is used as a biomarker for hepatobiliary cancer and is generally not considered helpful in the evaluation of gynecologic cancer. Endometriosis-associated cancers are a subset of gynecologic cancers in which malignancy is found adjacent to endometriosis either within or outside the gynecologic tract. We describe a case of a woman who presented with a CA 19-9 level of 49,469 U/mL who was subsequently found to have two concurrent but separate primary endometriosis-associated cancers involving the ovary and small intestine. Although data regarding the association between CA 19-9 and endometriosis-associated malignancy is lacking, endometriosis is known to be associated with high levels of inflammation which in turn has been associated with higher CA 19-9 levels. The inflammatory response and effect on CA 19-9 levels may be particularly pronounced in cases where endometriosis-associated malignancy involves the peritoneum. The case described suggests that when cancer is suspected in a woman with an extremely high level of CA 19-9 and no apparent hepatobiliary disease, an endometriosis-associated malignancy may be a consideration.